{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Aronson SL"],"pubmed_abstract":["While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, their efficacy in high-grade serous ovarian cancer (HGSOC) remains limited. Some patients, however, achieve lasting responses, emphasizing the need to understand how tumor microenvironment and molecular characteristics influence ICI response. The phase 2 Neo-Pembro study (NCT03126812) included 33 untreated stage IV HGSOC patients, who were scheduled for 6 cycles of carboplatin-paclitaxel and interval cytoreductive surgery. Pembrolizumab (pembro) was added from cycle two and continued for one year. The primary objective was to assess intratumoral immune activation using multiplexed immunofluorescence and immune-related gene expression. Our findings show immune activation, evidenced by an increase in CD3 + , CD8 "],"journal":["Nature communications"],"pagination":["3520"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11997049"],"repository":["biostudies-literature"],"pubmed_title":["Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial."],"pmcid":["PMC11997049"],"pubmed_authors":["Koole SN","van den Broek D","van Driel WJ","van der Leest P","Rijlaarsdam MA","Lahaye MJ","Aronson SL","Mandjes IAM","Holtkamp MJ","Broeks A","Seignette IM","Sanders J","Kemper I","Leon-Castillo A","Horlings HM","Thijssen B","Lopez-Yurda M","Wessels LFA","Alkemade M","Sonke GS","Harkes R"],"additional_accession":[]},"is_claimable":false,"name":"Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.","description":"While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, their efficacy in high-grade serous ovarian cancer (HGSOC) remains limited. Some patients, however, achieve lasting responses, emphasizing the need to understand how tumor microenvironment and molecular characteristics influence ICI response. The phase 2 Neo-Pembro study (NCT03126812) included 33 untreated stage IV HGSOC patients, who were scheduled for 6 cycles of carboplatin-paclitaxel and interval cytoreductive surgery. Pembrolizumab (pembro) was added from cycle two and continued for one year. The primary objective was to assess intratumoral immune activation using multiplexed immunofluorescence and immune-related gene expression. Our findings show immune activation, evidenced by an increase in CD3 + , CD8 ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T17:56:43.762Z","creation":"2025-06-26T03:06:19.965Z"},"accession":"S-EPMC11997049","cross_references":{"pubmed":["40229272"],"doi":["10.1038/s41467-025-58440-y"]}}